Cardiovascular Diagnosis Using µ-Cor - an Interventional Pilot Trial

Cardiovascular Diagnosis Using µ-Cor - an Interventional Pilot Trial

Subjects that are being treated at the Congestive Heart Failure clinic in Nazareth will be given the µ-Cor system to be added to their standard care, and randomized 1:1 to an interventional arm or a control arm.

Inclusion Criteria:

• Men or women 20-90 years old.
• New York Heart Association (NYHA) class III-IV heart failure
• Followed by the Congestive Heart Failure (CHF) clinic in Nazareth
• Left ventricular ejection fraction <35%
• Requiring treatment with >40mg/day of furosemide* orally or with repeated bolus or intravenous infusion of furosemide* (*or equivalent bumetanide or torasemide).

Exclusion Criteria:

• Pregnancy
• Subjects who have received a heart transplant.
• Subjects who are unable or unwilling to follow the study requirements.
• Patients with allergies or skin sensitivities to electrode hydrogel and/or acrylic based adhesive.
• Patients with skin breakdown in areas on the chest where device and electrode placement is required